Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

New Electronic Pipette Designed for Accuracy and Comfort

By BiotechDaily International staff writers
Posted on 30 Jul 2013
A new line of electronic pipettes ensures error-free and comfortable pipetting even when performing repetitive routine procedures.

The INTEGRA Biosciences AG (Zizers, Switzerland) PIPETBOY pro weighs only 190 grams and was ergonomically designed for a comfortable fit in order to reduce the labor involved in prolonged pipetting tasks.

The PIPETBOY pro is a precision instrument that enables accurate liquid transfer at variable speeds that is controlled by finger pressure on the pipette's trigger. The user can dispense liquids drop-by-drop with slight pressure on the trigger, or, by fully pressing on the trigger, engage the powerful pump motor to quickly empty the pipette. Accurate and reliable results can be achieved quickly even by occasional users at pipetting speeds of up to 12 milliliters per second.

INTEGRA, a leading supplier of high-quality laboratory tools for liquid handling, media preparation, sterilization, and cell cultivation, has added a clever innovation to the PIPETBOY pro. The pipette is outfitted with an integral white LED light that provides strong illumination of the area around the pipette, ensuring accurate pipetting and preventing eyestrain.

Related Links:

INTEGRA Biosciences AG



Channels

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.